What a great company! and long term hold!
- Q1 2015 Sales of $3,306,100 increased by 35% versus Q1 2014
- Q1 2015 Revenue grew at a compound annual growth rate (CAGR) of 54% over the last 3 years
- Q1 2015 Pharmaceutical Sales of $3,229,276 up 38% versus Q1 2013
- Q1 2015 EBITDA1 of $1,314,324 increased by 92% over Q1 2014
- Q1 2015 Net Income After Tax of $962,712 increased by 88% over Q1 2014
- Net Income After Tax Margin increased from 21% in Q1 2014 to 29 % Q1 2015
- Q1 2015 Fully Diluted EPS of $0.07 increased by 75% versus $0.04 in Q1 2014
- Trailing Twelve Month (TTM) fully diluted EPS of $0.25 was 67% higher than $0.15 in the TTM period ending March 31, 2014
- The Company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada
- Hospital Business Unit with dedicated staff was established in Q1 2015
- Aguettant System® Atropine pre filled syringe (PFS) launched in February 2015
- Shipments to two new international markets
Total sales for Q1 2015 of $3,306,100, were 35% higher compared to $2,448,101 in the corresponding prior year period.
EBITDA1 for Q1 2015 of $1,314,324 was 92% higher than $686,283 in Q1 2014.
Q1 2015 Net Income After Tax of $962,712 increased by 88% over $511,421in Q1 2014.
Read more at https://www.stockhouse.com/news/press-releases/2015/05/13/biosyent-releases-first-quarter-2015-results-sales-up-35-pharma-sales-up-38#9T7tJO0YJFhKScxG.99